Liraglutide

Liraglutide
ATC Code A08AX02, A10BJ02
Formula C172H265N43O51
Physical State solid
CAS Number 204656-20-2
PUB Number 16134956
Drugbank ID DB06655

Basics

Liraglutide is a so-called incretin mimetic or GLP-1 analog. It is used to treat type 2 diabetes mellitus and to prevent cardiovascular complications associated with diabetes. In addition, it is approved for the treatment of obesity above a BMI of 30 in combination with dietary measures. It is administered as a subcutaneous injection.

Liraglutide was developed by Novo-Nordisk and was approved in the United States in 2010 and in the European Union in 2009.

Pharmacology

Pharmacodynamics

Liraglutide is a synthetically produced analog of the endogenous "glucagon-like-peptide-1" (GLP-1). The major advantage of this active ingredient lies in its modified structure, as it has a greatly extended retention time in the blood due to the addition of a fatty acid and a slight modification of the amino acid sequence. The endogenously occurring GLP-1, on the other hand, is broken down in the body by the body's own enzymes in the intestine after only about 1-2 minutes.

Like GLP-1, liraglutide binds to the glucagon-like peptide-1 receptor. Binding to the receptor and the resulting increase in cyclic AMP stimulates the glucose-dependent release of insulin, inhibits the glucose-dependent release of glucagon, and slows gastric emptying. Through these mechanisms, post-meal blood glucose levels are kept low.

Pharmacokinetics

The bioavailability of liraglutide after subcutaneous injection is approximately 55% and the maximum plasma concentration is reached after approximately 11 hours. Liraglutide is present in the blood more than 98% bound to serum albumin. Due to its altered structure, liraglutide is degraded and metabolized much more slowly by the enzyme dipeptidyl peptidase-4 (DPP4), which is why its plasma half-life is about 13 hours.

Toxicity

Side effects

  • Nausea
  • Emesis
  • Diarrhea
  • constipation
  • Headache

In rare cases, pancreatitis may occur. A slightly increased risk of developing medullary thyroid carcinoma is associated with its use.

Editorial principles

All information used for the content comes from verified sources (recognised institutions, experts, studies by renowned universities). We attach great importance to the qualification of the authors and the scientific background of the information. Thus, we ensure that our research is based on scientific findings.

Markus Falkenstätter

Markus Falkenstätter
Author

Markus Falkenstätter is a writer on pharmaceutical topics in Medikamio's medical editorial team. He is in the last semester of his pharmacy studies at the University of Vienna and loves scientific work in the field of natural sciences.

Mag. pharm Stefanie Lehenauer

Mag. pharm Stefanie Lehenauer
Lector

Stefanie Lehenauer has been a freelance writer for Medikamio since 2020 and studied pharmacy at the University of Vienna. She works as a pharmacist in Vienna and her passion is herbal medicines and their effects.

Your personal medicine assistent

afgis-Qualitätslogo mit Ablauf Jahr/Monat: Mit einem Klick auf das Logo öffnet sich ein neues Bildschirmfenster mit Informationen über Medikamio GmbH & Co KG und sein/ihr Internet-Angebot: medikamio.com/ This website is certified by Health On the Net Foundation. Click to verify.
Drugs

Search our database for drugs, sorted from A-Z with their effects and ingredients.

Substances

All substances with their common uses, chemical components and medical products which contain them.

Diseases

Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.